Strong Q4 and full year at Biogen Idec as pipeline continues to cause concern
This article was originally published in Scrip
Executive Summary
The fourth quarter was "a good finish to a very good year", said Biogen Idec's CEO Dr George Scangos. Net profit fell by 21% to $240 million, or 99 cents a share, due to restructuring, but excluding one-time items, the company earned $1.42 a share, or $347 million.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.